Physician profile
Osama Malak
NPI 1245218775
$3,823.03
in general payments reported to CMS, 2019-2025
46 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $405 · 2021: $403 · 2022: $867 · 2023: $616 · 2024: $292 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.14 | 2021-2024 | |
| Abbott Laboratories | $380.71 | 2019-2025 | Eterna, Proclaim |
| Collegium Pharmaceutical, INC. | $276.65 | 2019-2024 | Xtampza |
| Azurity Pharmaceuticals, INC. | $198.78 | 2023-2025 | Horizant, Horizant |
| Vertos Medical, INC. | $191.44 | 2019-2023 | Mild Device Kit |
| Medtronic, INC. | $178.65 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $153.07 | 2022-2024 | Ztlido |
| Nevro Corp. | $138.96 | 2019-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.57 | 2019-2024 | Relistor |
| Pacira Pharmaceuticals Incorporated | $118.11 | 2023-2025 | Exparel, Zilretta, Iovera |
| Amgen INC. | $117.60 | 2019-2022 | |
| Flowonix Medical Incorporated | $116.68 | 2019 | |
| Pfizer INC. | $109.77 | 2019-2025 | |
| Boston Scientific Corporation | $91.34 | 2020-2023 | Wavewriter Alpha Prime 16 |
| Averitas Pharma INC. | $87.91 | 2025 | Qutenza |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osama Malak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.